Adipotide (FTPP) 10mg
Adipotide, also known as FTPP, is an experimental weight loss treatment that kills fat cells by targeting the blood supply of those cells.
- Product Usage:
This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.
What is Adipotide?
Adipotide (a.k.a. FTPP or proapototic peptide) kills fat cells, plain and simple, by targeting the blood supply of those cells. Interestingly, adipotide is able to discern the blood vessels in fat cells from the blood vessels throughout the rest of the body and is therefore highly selective. Research in monkeys shows that adipotide not only causes weight loss, it actually boosts insulin sensitivity and offsets some of the effects of type 2 diabetes.
Adipotide Structure
Sequence: Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Cys—Gly-Gly–(Lys-Leu-Ala-Lys-Leu-Ala-Lys)2
Molecular Formula: C152H252N44O42
Molecular Weight: 2611.41 g/mol
Adipotide Research
1. Adipotide And Fat Loss
Adipotide was developed and placed into phase I clinical trials in 2011 to investigate its ability to kill fat cells. Tests in rhesus monkeys revealed that adipotide causes targeted apoptosis in the blood vessels of white adipose tissue (fat). Without a blood supply, the fat cells simply died. The net result was rapid weight loss, rapid decrease in body mass index (BMI), and improved insulin resistance characteristics. Interestingly, treatment with adipotide and subsequent fat loss not only improved weight, but actually contributed to changes in eating behavior. Monkeys who lost weight with adipotide also showed a decrease in food consumption
B. Percent reduction in BMI (control versus treatment)
B. Shows the insulinogenic index for before and after in the treatment (red) and control (blue) groups. Treated groups show a dramatic decrease in insulin secretion.
C. Change in biscuit consumption in treated (red) and control (blue) groups.
The targeting of adipotide to the blood vessels serving fat cells may be mediated by a protein receptor called prohibitin. Prohibitin is a membrane protein that may only be found in blood vessels serving white fat and in cancer cells. It has been demonstrated that adipotide associates with this protein
2. Adipotide and Cancer
3. Adipotide and Glucose Tolerance
Future Adipotide Research
The primary area of adipotide research is in fat loss and diabetes. The peptide targets specific cells in the blood vessels that supply fat tissue, causing those blood vessels to die and, as a result, causing the fat cells they supply to die. Adipotide is an anti-angiogenic peptide, which means it targets blood vessels. Anti-angiogenic molecules are of keen interest right now in the treatment of cancer. There is limited, but promising research, on the role of adipotide in cancer.
Adipotide exhibits minimal side effects, low oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans. Adipotide for sale at Peptide Sciences is limited to educational and scientific research only, not for human consumption. Only buy Adipotide if you are a licensed researcher.
Adipotide Resources
- K. F. Barnhart et al., “A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys,” Sci. Transl. Med., vol. 3, no. 108, p. 108ra112, Nov. 2011.
- M. G. Kolonin, P. K. Saha, L. Chan, R. Pasqualini, and W. Arap, “Reversal of obesity by targeted ablation of adipose tissue,” Nat. Med., vol. 10, no. 6, pp. 625–632, Jun. 2004.
- F. I. Staquicini et al., “Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients,” Proc. Natl. Acad. Sci. U. S. A., vol. 108, no. 46, pp. 18637–18642, Nov. 2011.
- D.-H. Kim et al., “Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium,” Diabetes, vol. 61, no. 9, pp. 2299–2310, Sep. 2012.
- L. Criscione, “Comment on ‘a peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys,’” Sci. Transl. Med., vol. 4, no. 131, pp. 131le2; author reply 131lr2, Apr. 2012.
- Barnhart KF, Christianson DR, Hanley PW, et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys.
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.
